Adia Nutrition Inc. Identifies Over 20 Million Potentially Improperly Issued Shares and Initiates Process to Return Shares to Treasury

Core Viewpoint - Adia Nutrition Inc. has identified over 20 million potentially improperly issued shares and is initiating a process to return these shares to the treasury as part of an internal audit aimed at enhancing the integrity of its capitalization [1][2]. Group 1: Company Actions - The company has confirmed with legal counsel to seek the cancellation of the identified shares and their return to the treasury, which is expected to strengthen the share structure without affecting ongoing operations [3]. - The CEO emphasized the commitment to corporate governance and shareholder value, stating that addressing these historical issues is crucial for the company's sustained growth in the regenerative medicine sector [4]. Group 2: Business Focus - Adia Nutrition Inc. is dedicated to advancing stem cell therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis, and treatments for orthopedic conditions, chronic pain, and complex wound repair [4]. - The company operates two key divisions: a supplement division providing premium organic supplements and a medical division establishing clinics specializing in advanced stem cell therapies [6]. Group 3: Strategic Partnerships - The company encourages clinic owners and healthcare practitioners to license the Adia Med name or integrate its regenerative therapies into their practices, highlighting a focus on strategic partnerships to expand access to advanced stem cell solutions [5].